Fruquintinib in patients with metastatic colorectal cancer failed in previously bevacizumab-based therapy: A monocentric retrospective study.

被引：0
|
作者：
Gu, Xiaoqiang [1 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, LongHua Hosp, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15555
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Satoshi Matsusaka
    Mitsukuni Suenaga
    Yuji Mishima
    Koichi Takagi
    Yasuhito Terui
    Nobuyuki Mizunuma
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 763 - 768
  • [22] Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
    Fiala, Ondrej
    Ostasov, Pavel
    Sorejs, Ondrej
    Liska, Vaclav
    Buchler, Tomas
    Poprach, Alexandr
    Finek, Jindrich
    CANCERS, 2019, 11 (12)
  • [23] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Matsusaka, Satoshi
    Suenaga, Mitsukuni
    Mishima, Yuji
    Takagi, Koichi
    Terui, Yasuhito
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 763 - 768
  • [24] Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimen
    Yildiz, R.
    Buyukberber, S.
    Uner, A.
    Yamac, D.
    Coskun, U.
    Kaya, A. O.
    Ozturk, B.
    Yaman, E.
    Benelkli, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 143 - 143
  • [25] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [26] Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy
    Yildiz, Ibrahim
    Sen, Fatma
    Kilic, Leyla
    Keskin, Serkan
    Ciftci, Rumeysa
    Ekenel, Meltem
    Aykan, Nuri Faruk
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Circulating endothelial cells in advanced colorectal cancer patients treated with bevacizumab-based combination therapy: A flow cytometric study
    Bencardino, K.
    Manzoni, M.
    Rovati, B.
    Mariucci, S.
    Brugnatelli, S.
    Chatzileontiadou, S.
    Danova, M.
    CYTOMETRY PART A, 2008, 73A (01) : 64 - 64
  • [28] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [29] Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy.
    Ulivi, Paola
    Marisi, Giorgia
    Scarpi, Emanuela
    Passardi, Alessandro
    Ragazzini, Angela
    Frassineti, Giovanni Luca
    Zoli, Wainer
    Valgiusti, Martina
    Nanni, Oriana
    Calistri, Daniele
    Casacci, Fabio
    Amadori, Dino
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
12345